Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer
Journal of Bone and Mineral Metabolism · 2023-05 · 41 (3) · 307-316
DOI: 10.1007/s00774-023-01414-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Bone and Mineral Metabolism, online erschienen am 10.04.2023. Verfasst von Shunji Takahashi. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan. s.takahas…. Hauptthemen laut MEDLINE: Breast Neoplasms, Prostatic Neoplasms, Bone Diseases, Metabolic, Fractures, Bone. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 101 Literaturangaben.
Abstract (Originalsprache)
Breast cancer and prostate cancer are sex hormone-dependent cancers, and estrogen or androgen suppression therapy is the standard treatment. Cancer treatment-induced bone loss (CTIBL): bone loss and osteoporosis have become important side effects of these therapies. To summarize the current evidences, (1) Endocrine therapy for breast cancer and prostate cancer is associated with a significant decrease in bone mineral density. (2) Aromatase inhibitors (AI) for breast cancer are associated with a significant increase in fractures, and androgen deprivation therapy (ADT) for prostate cancer is likely to be associated with an increase in fractures. (3) Administration of bisphosphonates and denosumab increases bone mass in patients undergoing endocrine therapy for breast cancer. Administration of bisphosphonates, denosumab, and SERMs increased bone mass in patients undergoing ADT therapy for prostate cancer. (4) Bisphosphonates and denosumab reduce fracture risk in patients on AI for breast cancer, and toremifene and denosumab in patients on ADT for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, Japan. s.takahashi-chemotherapy@jfcr.or.jp.
Zitieren
APA
Takahashi, S. (2023). Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer. Journal of Bone and Mineral Metabolism, 41(3), 307-316. https://doi.org/10.1007/s00774-023-01414-1
Vancouver
Takahashi S. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer. Journal of Bone and Mineral Metabolism. 2023;41(3):307-316. doi:10.1007/s00774-023-01414-1
BibTeX
@article{Takahashi2023,
author = {Takahashi, Shunji},
title = {Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer},
journal = {Journal of Bone and Mineral Metabolism},
year = {2023},
volume = {41},
number = {3},
pages = {307--316},
doi = {10.1007/s00774-023-01414-1}
}
EUVIMED